Assertio and Garda Mutually Extend Tender Offer Deadline to May 4
summarizeSummary
Assertio Holdings and Garda Therapeutics have mutually agreed to extend the deadline for Garda's tender offer to acquire Assertio to May 4, 2026. This development follows the April 21st announcement of Garda's intent to commence the tender offer. The original definitive agreement, valued at $18.00 per share in cash plus a contingent value right, included a 20-day "window-shop" period for Assertio to seek superior bids. While a procedural update, this extension impacts the timeline of the ongoing acquisition and could provide additional time for potential competing offers to emerge, which could be a slight positive for shareholders. Investors should monitor for the commencement of the tender offer and any further developments regarding potential superior bids.
At the time of this announcement, ASRT was trading at $18.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.3M. The 52-week trading range was $8.61 to $20.45. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.